Treatment of spastic esophageal motility disorders

Gastroenterology Clinics of North America

Volumn 33, Issue 1, 2004, Pages 107-124

  Achem, Sami R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ARGININE; ATROPINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETROPIUM; CLOMIPRAMINE; DESIPRAMINE; DILTIAZEM; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYOSCYAMINE; IMIPRAMINE; NIFEDIPINE; NITRATE; NITRIC OXIDE; PEPPERMINT OIL; PIRENZEPINE; PROPANTHELINE BROMIDE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; COLITIS; EJACULATION DISORDER; ESOPHAGUS ACHALASIA; ESOPHAGUS FUNCTION DISORDER; ESOPHAGUS SPASM; HEADACHE; HUMAN; HYPERALGESIA; HYPOTENSION; LIBIDO DISORDER; NOCICEPTION; NONHUMAN; PRIAPISM; RESTLESSNESS; REVIEW; SEDATION; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; VISCERAL PAIN; XEROSTOMIA;

CHEST PAIN; ESOPHAGEAL MOTILITY DISORDERS; HUMANS; HYPERALGESIA; PERCEPTION; PSYCHOTROPIC DRUGS; SEROTONIN UPTAKE INHIBITORS; VISCERA;

EID: 1642380157     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8553(03)00129-8     Document Type: Review

References (105)

1. Spechler S.J., Castell D.O. Classification of oesophageal motility abnormalities. Gut. 49:2001;145-151.
2. Kahrilas P.J. Esophageal motility disorders: current concepts of pathogenesis and treatment. Can J Gastroenterol. 14:2000;221-231.
3. Richter J.E. Oesophageal motility disorders. Lancet. 358:2001;823-828.
4. Richter J.E., Dalton C.B., Bradley L.A., Castell D.O. Oral nifedipine in the treatment of noncardiac chest pain in patients with the nutcracker esophagus. Gastroenterology. 93:1987;21-28.
5. Rao S.S., Hayek B., Summers R.W. Functional chest pain of esophageal origin: hyperalgesia or motor dysfunction. Am J Gastroenterol. 96:2001;2584-2589.
6. Kahrilas P.J. Nutcracker esophagus: an idea whose time has gone? Am J Gastroenterol. 88:1993;167-169.
7. Clouse R.E., Lustman P.J., Eckert T.C., Ferney D.M., Griffith L.S. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities: a double-blind, placebo-controlled trial. Gastroenterology. 92:1987;1027-1036.
8. Achem S.R., Kolts B.E. Current medical therapy for esophageal motility disorders. Am J Med. 92:1992;98S-105S.
9. Achem S.R., DeVault K.R. Unexplained chest pain at the turn of the century. [editorial] Am J Gastroenterol. 94:1999;5-8.
10. Storr M., Allescher H.D. Esophageal pharmacology and treatment of primary motility disorders. Dis Esophagus. 12:1999;241-257.
11. Orlando R.C., Bozymski E.M. Clinical and manometric effects of nitroglycerin in diffuse esophageal spasm. N Engl J Med. 289:1973;23-25.
12. Swamy N. Esophageal spasm: clinical and manometric response to nitroglycerine and long acting nitrites. Gastroenterology. 72:1977;23-27.
13. Preiksaitis H.G., Tremblay L., Diamant N.E. Nitric oxide mediates inhibitory nerve effects in human esophagus and lower esophageal sphincter. Dig Dis Sci. 39:1994;770-775.
14. Anand N., Paterson W.G. Role of nitric oxide in esophageal peristalsis. Am J Physiol. 266:1994;G123-G131.
15. Murray J.A., Ledlow A., Launspach J., Evans D., Loveday M., Conklin J.L. The effects of recombinant human hemoglobin on esophageal motor functions in humans. Gastroenterology. 109:1995;1241-1248.
16. Konturek J.W., Thor P., Lukaszyk A., Gabryelewicz A., Konturek S.J., Domschke W. Endogenous nitric oxide in the control of esophageal motility in humans. J Physiol Pharmacol. 48:1997;201-209.
17. Boger R.H., Bode-Boger S.M. The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol. 41:2001;79-99.
18. Konturek J.W., Gillessen A., Domschke W. Diffuse esophageal spasm: a malfunction that involves nitric oxide? Scand J Gastroenterol. 30:1995;1041-1045.
19. Luiking Y.C., Weusten B.L., Portincasa P., Van Der Meer R., Smout A.J., Akkermans L.M. Effects of long-term oral L-arginine on esophageal motility and gallbladder dynamics in healthy humans. Am J Physiol. 274:1998;G984-G991.
20. Bortolotti M., Brunelli F., Sarti P., Miglioli M. Clinical and manometric effects of L-arginine in patients with chest pain and oesophageal motor disorders. Ital J Gastroenterol Hepatol. 29:1997;320-324.
21. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 329:1993;2002-2012.
22. Cannon R.O. III, Cattau E.L. Jr., Yakshe P.N., Maher K., Schenke W.H., Benjamin S.B., et al. Coronary flow reserve, esophageal motility, and chest pain in patients with angiographically normal coronary arteries. Am J Med. 88:1990;217-222.
23. Lerman A., Burnett J.C. Jr., Higano S.T., McKinley L.J., Holmes D.R. Jr. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 97:1998;2123-2128.
24. Eherer A.J., Schwetz I., Hammer H.F., Petnehazy T., Scheidl S.J., Weber K., et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut. 50:2002;758-764.
25. Hollis J.B., Castell D.O. Effects of cholinergic stimulation on human esophageal peristalsis. J Appl Physiol. 40:1976;40-43.
26. Greenwood B. Muscarinic receptor regulation of the esophagus and lower esophageal sphincter. Dysphagia. 9:1994;206-208.
27. Bonner T.I., Buckley N.J., Young A.C., Brann M.R. Identification of a family of muscarinic acetylcholine receptor genes. Science. 237:1987;527-532.
28. Wang J., Krysiak P.S., Laurier L.G., Sims S.M., Preiksaitis H.G. Human esophageal smooth muscle cells express muscarinic receptor subtypes M(1) through M(5). Am J Physiol Gastrointest Liver Physiol. 279:2000;G1059-G1069.
29. Dodds W.J., Dent J., Hogan W.J., Arndorfer R.C. Effect of atropine on esophageal motor function in humans. Am J Physiol. 240:1981;G290-G296.
30. Phaosawasdi K., Malmud L.S., Tolin R.D., Stelzer F., Applegate G., Fisher R.S. Cholinergic effects on esophageal transit and clearance. Gastroenterology. 81:1981;915-920.
31. Jaup B.H., Abrahamsson H., Virtanen R., Iisalo E. Effect of pirenzepine compared with atropine and L-hyoscyamine on esophageal peristaltic activity in humans. Scand J Gastroenterol. 17:1982;233-239.
32. Paterson W.G., Selucky M., Hynna-Liepert T.T. Effect of intraesophageal location and muscarinic blockade on balloon distension-induced chest pain. Dig Dis Sci. 36:1991;282-288.
33. Blackwell J.N., Dalton C.B., Castell D.O. Oral pirenzepine does not affect esophageal pressures in man. Dig Dis Sci. 31:1986;230-235.
34. Erckenbretch E., Berges W., Sonnenberg A. The effects of pirenzipine on esophageal motility. Scand J Gastroenterol. 72:1982;185-190.
35. Hongo M., Traube M., McCallum R.W. Comparison of effects of nifedipine, propantheline bromide, and the combination on esophageal motor function in normal volunteers. Dig Dis Sci. 29:1984;300-304.
36. Bassotti G., Gaburri M., Imbimbo B.P., Betti C., Daniotti S., Pelli M.A., et al. Manometric evaluation of cimetropium bromide activity in patients with the nutcracker oesophagus. Scand J Gastroenterol. 23:1988;1079-1084.
37. Pasricha P.J., Rai R., Ravich W.J., Hendrix T.R., Kalloo A.N. Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology. 110:1996;1410-1415.
38. Birgisson S., Richter J.E. Achalasia: what's new in diagnosis and treatment? Dig Dis. 15:1997;1-27.
39. Miller L.S., Parkman H.P., Schiano T.D., Cassidy M.J., Ter R.B., Dabezies M.A., et al. Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. Dig Dis Sci. 41:1996;2025-2031.
40. Miller L.S., Pullela S.V., Parkman H.P., Schiano T.D., Cassidy M.J., Cohen S., et al. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal. Am J Gastroenterol. 97:2002;1640-1646.
41. Storr M., Allescher H.D., Rosch T., Born P., Weigert N., Classen M. Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: a prospective study with long-term follow-up. Gastrointest Endosc. 54:2001;754-759.
42. Nebendahl J.C., Brand B., von Schrenck T., Matsui U., Bohnacker S., Seitz U., et al. Treatment of diffuse esophageal spasm with botulinum toxin: a prospective study with 6 months' follow up. Gastrointest Endosc. 49:1999;A302.
43. Cassidy M.J., Schiano T.D., Adrain A.L., Parkman H.P., Cohen S., Fisher R.S., et al. Botulinum toxin injection for the treatment of symptomatic diffuse esophageal spasm. Am J Gastroenterol. 91:1996;1884.
44. Jones M.P. Botulinum toxin in hypertensive lower esophageal sphincter. [letter] Am J Gastroenterol. 91:1996;1283-1284.
45. Traube M., McCallum R.W. Calcium-channel blockers and the gastrointestinal tract. American College of Gastroenterology's Committee on FDA related matters. Am J Gastroenterol. 79:1984;892-896.
46. Cohen S., Green F. The mechanics of esophageal muscle contraction: evidence of an inotropic effect of gastrin. J Clin Invest. 52:1973;2029-2040.
47. de Carle D.J., Christensen J., Szabo A.C., Templeman D.C., McKinley D.R. Calcium dependence of neuromuscular events in esophageal smooth muscle of the opossum. Am J Physiol. 232:1977;E547-E552.
48. Blackwell J.N., Holt S., Heading R.C. Effect of nifedipine on oesophageal motility and gastric emptying. Digestion. 21:1981;50-56.
49. Richter J.E., Spurling T.J., Cordova C.M., Castell D.O. Effects of oral calcium blocker, diltiazem, on esophageal contractions: studies in volunteers and patients with nutcracker esophagus. Dig Dis Sci. 29:1984;649-656.
50. Cattau E.L. Jr., Castell D.O., Johnson D.A., Spurling T.J., Hirszel R., Chobanian S.J., et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol. 86:1991;272-276.
51. Drenth J.P., Bos L.P., Engels L.G. Efficacy of diltiazem in the treatment of diffuse oesophageal spasm. Aliment Pharmacol Ther. 4:1990;411-416.
52. Goyal R.K., Rattan S. Effects of sodium nitroprusside and verapamil on lower esophageal sphincter. Am J Physiol. 238:1980;G40-G44.
53. Richter J.E., Sinar D.R., Cordova C.M., Castell D.O. Verapamil: a potent inhibitor of esophageal contractions in the baboon. Gastroenterology. 82:1982;882-886.
54. Allen M., Mellow M., Robinson M.G., Orr W.C. Comparison of calcium channel blocking agents and an anticholinergic agent on oesophageal function. Aliment Pharmacol Ther. 1:1987;153-159.
55. Clouse R.E., Lustman P.J. Psychiatric illness and contraction abnormalities of the esophagus. N Engl J Med. 309:1983;1337-1342.
56. Richter J.E., Barish C.F., Castell D.O. Abnormal sensory perception in patients with esophageal chest pain. Gastroenterology. 91:1986;845-852.
57. Richter J.E., Obrecht W.F., Bradley L.A., Young L.D., Anderson K.O. Psychological comparison of patients with nutcracker esophagus and irritable bowel syndrome. Dig Dis Sci. 31:1986;131-138.
58. Bass C., Wade C. Chest pain with normal coronary arteries: a comparative study of psychiatric and social morbidity. Psychol Med. 14:1984;51-61.
59. Bromm B., Meier W., Scharein E. Imipramine reduces experimental pain. Pain. 25:1986;245-257.
60. Myren J., Lovland B., Larssen S.E., Larsen S. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol. 19:1984;835-843.
61. Prakash C., Clouse R.E. Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci. 44:1999;2373-2379.
62. Cannon R.O. III, Quyyumi A.A., Mincemoyer R., Stine A.M., Gracely R.H., Smith W.B., et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 330:1994;1411-1417.
63. Peghini P.L., Katz P.O., Castell D.O. Imipramine decreases oesophageal pain perception in human male volunteers. Gut. 42:1998;807-813.
64. Handa M., Mine K., Yamamoto H., Hayashi H., Tsuchida O., Kanazawa F., et al. Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach. J Clin Gastroenterol. 28:1999;228-232.
65. Cannon R.O. III. Does coronary endothelial dysfunction cause myocardial ischemia in the absence of obstructive coronary artery disease? Circulation. 96:1997;3251-3254.
66. Varia I., Logue E., O'Connor C., Newby K., Wagner H.R., Davenport C., et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J. 140:2000;367-372.
67. O'Malley P.G., Jackson J.L., Santoro J., Tomkins G., Balden E., Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract. 48:1999;980-990.
68. Jung A.C., Staiger T., Sullivan M. The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. J Gen Intern Med. 12:1997;384-389.
69. Pimentel M., Bonorris G.G., Chow E.J., Lin H.C. Peppermint oil improves the manometric findings in diffuse esophageal spasm. J Clin Gastroenterol. 33:2001;27-31.
70. Massey B.T. Diffuse esophageal spasm: a case for carminatives? J Clin Gastroenterol. 33:2001;8-10.
71. Shapiro L.M., Crake T., Poole-Wilson P.A. Is altered cardiac sensation responsible for chest pain in patients with normal coronary arteries? Clinical observation during cardiac catheterization. Br Med J (Clin Res Ed). 296:1988;170-171.
72. Cannon R.O. III, Quyyumi A.A., Schenke W.H., Fananapazir L., Tucker E.E., Gaughan A.M., et al. Abnormal cardiac sensitivity in patients with chest pain and normal coronary arteries. J Am Coll Cardiol. 16:1990;1359-1366.
73. Chauhan A., Mullins P.A., Thuraisingham S.I., Taylor G., Petch M.C., Schofield P.M. Abnormal cardiac pain perception in syndrome X. J Am Coll Cardiol. 24:1994;329-335.
74. Lagerqvist B., Sylven C., Waldenstrom A. Lower threshold for adenosine-induced chest pain in patients with angina and normal coronary angiograms. Br Heart J. 68:1992;282-285.
75. Rosen S.D., Uren N.G., Kaski J.C., Tousoulis D., Davies G.J., Camici P.G. Coronary vasodilator reserve, pain perception, and sex in patients with syndrome X. Circulation. 90:1994;50-60.
76. Lasch H., DeVault K.R., Castell D.O. Intraesophageal balloon distention in the evaluation of sensory thresholds: studies on reproducibility and comparison of balloon composition. Am J Gastroenterol. 89:1994;1185-1190.
77. Nguyen P., Castell D.O. Evidence for sex differences in esophageal pain threshold. Gastroenterology. 104:1993;158A.
78. Hazan S., Steinberg A., Morris N., Affronti J., Achem S.R. Long-term reproducibility of intraesophageal balloon distension studies in patients with unexplained chest pain. Gastroenterology. 112:(Suppl):1997;A145.
79. Hu W.H., Talley N.J. Visceral perception in functional gastro-intestinal disorders: disease marker or epiphenomenon? Dig Dis. 14:1996;276-288.
80. Mertz H., Naliboff B., Munakata J., Niazi N., Mayer E.A. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology. 109:1995;40-52.
81. Kellow J.E. Sphincter of Oddi dysfunction type III: another manifestation of visceral hyperalgesia? [editorial] Gastroenterology. 116:1999;996-1000.
82. Plourde V., Lembo T., Shui Z., Parker J., Mertz H., Tache Y., et al. Effects of the somatostatin analogue octreotide on rectal afferent nerves in humans. Am J Physiol. 265:1993;G742-G751.
83. Bradette M., Delvaux M., Staumont G., Fioramonti J., Bueno L., Frexinos J. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci. 39:1994;1171-1178.
84. Hasler W.L., Soudah H.C., Owyang C. Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients. J Pharmacol Exp Ther. 268:1994;1206-1211.
85. Johnston B.T., Shils J., Leite L.P., Castell D.O. Effects of octreotide on esophageal visceral perception and cerebral evoked potentials induced by balloon distension. Am J Gastroenterol. 94:1999;65-70.
86. Hazan S., Buckley E., Castell D.O., Achem S.R. Octreotide improves sensory and pain thresholds in patients with noncardiac chest pain. Gastroenterology. 110:1996;A132.
87. Delvaux M., Louvel D., Mamet J.P., Campos-Oriola R., Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 12:1998;849-855.
88. Riviere P.J., Pascaud X., Chevalier E., Junien J.L. Fedotozine reversal of peritoneal-irritation-induced ileus in rats: possible peripheral action on sensory afferents. J Pharmacol Exp Ther. 270:1994;846-850.
89. Delvaux M., Louvel D., Lagier E., Scherrer B., Abitbol J.L., Frexinos J. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology. 116:1999;38-45.
90. Triadafilopoulos G., Tsang H.P., Segall G.M. Hot water swallows improve symptoms and accelerate esophageal clearance in esophageal motility disorders. J Clin Gastroenterol. 26:1998;239-244.
91. Klimes I., Mayou R.A., Pearce M.J., Coles L., Fagg J.R. Psychological treatment for atypical non-cardiac chest pain: a controlled evaluation. Psychol Med. 20:1990;605-611.
92. Achem S.R., Lyles W.E., Kolts B.E. Coexistence of reflux in patients with abnormal esophageal motility. Gastroenterol. 102:1992;31.
93. Achem S.R., Kolts B.E., MacMath T., Richter J., Mohr D., Burton L., et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci. 42:1997;2138-2145.
94. Achem S.R., Crittenden J., Kolts B., Burton L. Long-term clinical and manometric follow-up of patients with nonspecific esophageal motor disorders. Am J Gastroenterol. 87:1992;825-830.
95. Borjesson M., Pilhall M., Rolny P., Mannheimer C. Gastroesophageal acid reflux in patients with nutcracker esophagus. Scand J Gastroenterol. 36:2001;916-920.
96. Achem S.R., Kolts B.E., Wears R., Burton L., Richter J.E. Chest pain associated with nutcracker esophagus: a preliminary study of the role of gastroesophageal reflux. Am J Gastroenterol. 88:1993;187-192.
97. Fass R., Fennerty M.B., Ofman J.J., Gralnek I.M., Johnson C., Camargo E., et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology. 115:1998;42-49.
98. Parker W.A., MacKinnon G.L. Nitrites in the treatment of diffuse esophageal spasm. Drug Intell Clin Pharm. 15:1981;806-807.
99. Mellow M.H. Effect of isosorbide and hydralazine in painful primary esophageal motility disorders. Gastroenterology. 83:1982;364-370.
100. Millaire A., Ducloux G., Marquand A., Vaksmann G. Nitroglycerin and angina with angiographically normal coronary vessels. Clinical effects and effects on esophageal motility. Arch Mal Coeur Vaiss. 82:1989;63-68.
101. Davies H.A., Lewis M., Rhodes J., Henderson A. Nifedipine for relief of esophageal chest pain? N Engl J Med. 307:1982;1274.
102. Nasrallah S.M. Nifedipine in the treatment of diffuse oesophageal spasm. Lancet. 2:1982;1285.
103. Nasrallah S.M., Tommaso C.L., Singleton R.T., Backhaus E.A. Primary esophageal motor disorders: clinical response to nifedipine. South Med J. 78:1985;312-315.
104. Thomas E., Witt P., Willis M., Morse J. Nifedipine therapy for diffuse esophageal spasm. South Med J. 79:1986;847-849.
105. Banciu T., Iova M., Biroasiu G., Susan L. The diagnostic and therapeutic contribution of calcium channel inhibitors (nifedipine) in esophageal spasm. Med Interne. 28:1990;69-71.